Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents

Therapeutic Drug Monitoring

Volumn 34, Issue 5, 2012, Pages 535-544

  Sherwin, Catherine M T ^a   Saldaña, Shannon N ^b,c,d   Bies, Robert R ^e   Aman, Michael G ^f   Vinks, Alexander A ^c,d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

adolescent; children; CYP2D6; NONMEM; pharmacokinetics; risperidone

Indexed keywords

CYTOCHROME P450 2D6; PALIPERIDONE; RISPERIDONE;

ADOLESCENT; ADULT; AGE; ANALYTICAL ERROR; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; FEMALE; GENOTYPE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; POPULATION MODEL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEX; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; ISOXAZOLES; MALE; MENTAL DISORDERS; PHENOTYPE; PROSPECTIVE STUDIES; PYRIMIDINES; RISPERIDONE;

EID: 84866535376     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318261c240     Document Type: Article

References (44)

1. Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:213-235.
2. Myers SM, Johnson CP. Management of children with autism spectrum disorders. Pediatrics. 2007;120:1162-1182.
3. Pappadopulos E, Macintyre Ii JC, Crismon ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry. 2003;42:145-161.
4. Young CM, Findling RL. Pharmacologic treatment of adolescent and child schizophrenia. Expert Rev Neurother. 2004;4:53-60.
5. Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs. 2011;71:179-208.
6. McKinney C, Renk K. Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations. Clin Psychol Rev. 2011;31:465-471.
7. McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry. 2004;65(suppl 6):20-29.
8. Spina E, Avenoso A, Facciola G, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl). 2001;153:238-243.
9. He H, Richardson JS. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol. 1995;10:19-30.
10. Calarge CA, Miller del D. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psycho-pharmacol. 2011;21:163-169.
11. Locatelli I, Kastelic M, Koprivsek J, et al. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. Eur J Pharm Sci. 2010;41:289-298.
12. Novalbos J, Lopez-Rodriguez R, Roman M, et al. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J Clin Psychopharmacol. 2010;30:504-511.
13. Seto K, Dumontet J, Ensom MH. Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Ther Drug Monit. 2011;33:275-283.
14. Xiang Q, Zhao X, Zhou Y, et al. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol. 2010;50:659-666.
15. Megens AAHP, Awouters FHL. In vivo pharmacological profile of 9-hydroxyrisperidone, the major metabolite of the novel antipsychotic risperidone. Drug Develop Res. 1994;33:399-412.
16. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychophar-macology. 1995;122:223-229.
17. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229-243.
18. Aravagiri M, Marder SR, Nuechterlein KH, et al. Intra-and interindivid-ual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit. 2003;25:657-664.
19. Aravagiri M, Marder SR, Wirshing D, et al. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharma-copsychiatry. 1998;31:102-109.
20. Aichhorn W, Weiss U, Marksteiner J, et al. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol. 2005;19:395-401.
21. Yagihashi T, Mizuno M, Chino B, et al. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Hum Psychopharmacol. 2009;24:301-308.
22. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risper-idone, a new antipsychotic. J Pharmacol Exp Ther. 1988;247:661-670.
23. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124:57-73.
24. Feng Y, Pollock BG, Coley K, et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol. 2008;66:629-639.
25. Aichhorn W, Marksteiner J, Walch T, et al. Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol. 2007;17:665-674.
26. Leon J, Susce MT, Pan RM, et al. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry. 2007;40:93-102.
27. Aman MG, Vinks AA, Remmerie B, et al. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther. 2007;29:1476-1486.
28. Vinks AA, Mannaert E, Pappas K, et al. Pharmacokinetics of risperidone and its 9-hydroxy-enantiomer metabolites in pediatric psychiatric patients. Clin Pharmacol Ther. 2006;79:73.
29. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm. 1981;9:739-756.
30. D'Argenio DZ, Schumitzky A. ADAPT II. Pharmacokinetic/Pharmaco-dynamic Systems Analysis Software. User's Guide to Release 4. Los Angeles, CA: Biomedical Simulations Resource University of Southern California; 1997.
31. Flarakos J, Luo W, Aman M, et al. Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography-mass spectrometry. J Chromatogr A. 2004;1026:175-183.
32. Cabovska B, Cox SL, Vinks AA. Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS/MS. J Chro-matogr B Analyt Technol Biomed Life Sci. 2007;852:497-504.
33. Johansson I, Lundqvist E, Dahl ML, et al. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics. 1996;6:351-355.
34. Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene. 1999;226:327-338.
35. Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike information criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm. 1994;22:431-445.
36. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21:735-750.
37. Pohjalainen T, Rinne JO, Nagren K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry. 1998;3:256-260.
38. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303-332.
39. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr. 2006;165:741-746.
40. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486-495.
41. Ette EI, Sun H, Ludden TM. Ignorability and parameter estimation in longitudinal pharmacokinetic studies. J Clin Pharmacol. 1998;38:221-226.
42. Vermeulen A, Piotrovsky V, Ludwig EA. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. J Pharmacokinet Pharmacodyn. 2007; 34:183-206.
43. Thyssen A, Vermeulen A, Fuseau E, et al. Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clin Pharmacokinet. 2010;49:465-478.
44. Lemenuel-Diot A, Laveille C, Frey N, et al. Mixture modeling for the detection of subpopulations in a pharmacokinetic/pharmacodynamic analysis. J Pharmacokinet Pharmacodyn. 2007;34:157-181.